A phase I study of hydralazine to demythylate and reactivate the expression of tumor suppressor genes

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Zambrano, Pilar ^a   Segura Pacheco, Blanca ^a   Perez Cardenas, Enrique ^a   Cetina, Lucely ^b   Revilla Vazquez, Alma ^c   Taja Chayeb, Lucía ^a   Chavez Blanco, Alma ^a   Angeles, Enrique ^c   Cabrera, Gustavo ^a   Sandoval, Karina ^c   Trejo Becerril, Catalina ^a   Chanona Vilchis, Jose ^a   Duenas González, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APC PROTEIN; CYTOSINE; DEATH ASSOCIATED PROTEIN KINASE; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; HYDRALAZINE; PROTEIN P16; TUMOR SUPPRESSOR PROTEIN; 5 METHYLCYTOSINE; DNA; H19 LONG NON CODING RNA; H19 LONG NON-CODING RNA; LONG UNTRANSLATED RNA; UNTRANSLATED RNA; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLUSHING; GENE EXPRESSION; GENE SEQUENCE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN TISSUE; NAUSEA; PHASE 1 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TOXICITY TESTING; TUMOR BIOPSY; UTERINE CERVIX CANCER; VOMITING; BINDING SITE; BIOPSY; CARDIOVASCULAR DISEASE; CHEMISTRY; COHORT ANALYSIS; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR;

5-METHYLCYTOSINE; ADULT; AGED; BINDING SITES; BIOPSY; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYTOSINE; DNA; DNA METHYLATION; ELECTROPHORESIS, CAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYDRALAZINE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG UNTRANSLATED; RNA, UNTRANSLATED; UTERINE CERVICAL NEOPLASMS; VASODILATOR AGENTS;

EID: 26844499872     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-44     Document Type: Article

References (48)

1. Robertson KD: DNA methylation, methyltransferases and cancer. Oncogene 2001, 20:3139-55.
2. Pradhan S, Bacolla A, Wells RD, Roberts RJ: Recombinant human DNA (cytosine-5) methyltransferase.I. Expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999, 274:33002-10.
3. Beard C, Li E, Jaenisch R: methylation activates Xist in somatic but not in embryonic cells. Genes Dev 1995, 9:2325-34.
4. Li E, Beard C, Jaenisch R: Role for DNA methylation in genomic imprinting. Nature 1993, 366:362-5.
5. Leonhardt H, Page AW, Weier HU, Bestor TH: A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 1992, 71:865-73.
6. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for P21WAF1. Science 1997, 277:1996-2000.
7. Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-57.
8. Okano M, Xie S, Li E: Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. Nucleic Acids Res 1998, 26:2536-40.
9. Tate PH, Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993, 3:226-31.
10. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-81.
11. Rountree MR, Bachman KE, Baylin SB: DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genet 2000, 25:269-77.
12. Nan X, Ng HH, Johnson CA, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-9.
13. Bird A: The essentials of DNA methylation. Cell 1992, 70:5-8.
14. Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002, 21:5380-7.
15. Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993, 90:11995-9.
16. Baylin SB, Herman JG: DNA hyper methylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-74.
17. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134:573-86.
18. Bigey P, Knox JD, Croteau S, Bhattacharya SK, Theberge J, Szyf M: Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA. Hairpin antagonists of the human DNA methyltransferase. J Biol Chem 1999, 274:4594-606.
19. Lantry LE, Zhang Z, Crist KA, Wang Y, Kelloff GJ, Lubet RA, You M: 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 1999, 20:343-6.
20. Covey JM, Zaharko DS: Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2′-deoxycytidine with its therapeutic and toxic effects in mice. Eur J Cancer Clin Oncol 1985, 21:109-117.
21. Wu J, Issa JP, Herman J, Bassett DE, Nelking BD, Baylin SB: Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH3T3 cells. Proc Natl Acad Sci USA 1993, 90:8891-5.
22. Ramchandani S, MacLeod AR, Pinard M, Von Hofe E, Szyf M: Inhibition of tumorigenesis by a cytosine-DNA methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997, 94:684-9.
23. Goffin J, Eisenhauer E: DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002, 13:1699-716.
24. Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J, Rosenfeld C: Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs 2003, 4:1442-50.
25. Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK: A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003, 14:766-74.
26. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, Acuna C, Salazar AM, Lizano M, Duenas-Gonzalez A: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003, 9:1596-603.
27. Angeles E, Vazquez-Valadez VH, Vazquez-Valadez O, Velazquez-Sanchez AM, Ramirez A, Martinez L, Diaz-Barriga S, Romero-Rojas A, Cabrera G, Lopez-Castañares R, Duenas-Gonzalez A: Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. Lett Drug Design Discov 2005 in press.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-6.
29. Strichman-Almashanu LZ, Lee RS, Onyango PO, Perlman E, Flam F, Frieman MB, Feinberg AP: A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res 2002, 12:543-54.
30. Sandoval Guerrero K, Revilla Vazquez A, Segura-Pacheco B, Duenas-Gonzalez A: Determination of 5-methyl-cytosine and cytosine in tumor DNA samples of cancer patients. Electrophoresis 2005, 26:1057-62.
31. Pogribny I, Yi P, James SJ: A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 1999, 262:624-8.
32. Kirsten R, Nelson K, Kirsten D, Heintz B: Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet 1998, 35:9-36.
33. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P: Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003, 32:7955-60.
34. Klein L, O'Connor CM, Gattis WA, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M: Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003, 9:18F-40F.
35. Yung R, Chang S, Hemati N, Johnson K, Richardson B: Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997, 40:1436-43.
36. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001, 7:584-9.
37. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome. Mol Cancer 2003, 2:24-30.
38. Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001, 7:1982-6.
39. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lubbert M: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-64.
40. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-40.
41. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, Baker SD, Zhao M, Weber JS: Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2003, 51:231-9.
42. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-61.
43. Ludden TM, McNay JL Jr, Shepherd AM, Lin MS: Variability of plasma hydralazine concentrations in male hypertensive patients. Arthritis Rheum 1981, 24:987-93.
44. Dipierri JE, Alfaro E, Bejarano IF, Etchart AA: Acetylator phenotypes: allele frequency in northwestern Argentina and review of acetylator distribution in the Americas. Hum Biol 1998, 70:959-64.
45. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-53.
46. Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Dohner H, Wiessler M, Lyko F: Capillary electrophoretic analysis of genomic DNA methylation level. Nucleic Acids Res 2003, 31:E2.
47. Hu JF, Nguyen PH, Pham NV, Vu TH, Hoffman AR: Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol 1997, 11:1891-8.
48. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF: Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004, 22:1373-81.